Left Menu
Development News Edition

Sun Pharma initiates phase two clinical trial on AQCH as potential treatment for COVID-19 patients

Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19.

ANI | Mumbai (Maharashtra) | Updated: 05-06-2020 13:01 IST | Created: 05-06-2020 13:01 IST
Sun Pharma initiates phase two clinical trial on AQCH as potential treatment for COVID-19 patients
The company has 42 manufacturing facilities across six continents.. Image Credit: ANI

Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19. The company got approval from Drugs Controller General of India (DCGI) for conducting phase two clinical trial in April. The clinical trial will be conducted across 12 centres in India on 210 patients with a duration of 10 days.

The results of the clinical trial are expected by October. Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for phase two study. Managing Director Dilip Shanghvi said it is the first phytopharmaceutical drug approved for clinical trials by the DCGI as a potential treatment for COVID-19.

"AQCH has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Italy. These results combined with information on the mechanism of action through in-vitro and small animal studies give us the confidence to evaluate this potential treatment option for COVID-19 patients," he said in a statement on Friday. AQCH, which is being developed for dengue, has shown a broad antiviral effect in vitro studies and hence is being tested as a potential treatment option for COVID-19. Since 2016, Sun Pharma has been working closely with DBT-ICGEB under the leadership of Dr Navin Khanna and CSIR-IIIM under the leadership of Dr Ram Vishwakarma to develop a phytopharmaceutical drug for dengue.

The work on the evaluation of plant-derived drugs for the treatment of dengue started in 2007 under the auspices of the Department of Biotechnology's (DBT) Task Force on Medicinal and Aromatic Plants. Renu Swarup, Secretary of Department of Biotechnology, Ministry of Science and Technology, said: "Our efforts to develop a safe, effective and affordable drug against dengue started about 13 years ago. The collaborating team quickly initiated studies for the development of a drug against COVID-19. I wish the collaborating team success in the conduct of the clinical trial against COVID-19 and for the development of phytopharmaceutical drugs against other infectious diseases."

Shekhar C Mande, Director General of Council of Scientific and Industrial Research (CSIR), said: "CSIR has had a long-standing association with the pharmaceutical industry in India and welcomes this collaboration with Sun Pharma in taking forward AQCH into clinical trials for Covid-19 patients. This collaboration aligns with our scientific rationale for the quickest way to develop drugs against SARS-CoV-2." Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and India's top pharmaceutical company. Delivering products for customers and patients in over 100 countries, its global presence is supported by manufacturing facilities spread across six continents which are approved by multiple regulatory agencies. (ANI)



Why COVID-19 is unstoppable in USA despite it being ranked at the top of GHS Index?

Several worst-hit countries such as Italy, France, Spain, the UK, Canada, and Russia have peaked COVID-19 cases in April. Almost all of them have gradually flattened the curve. However, the USA is setting new daily records of infections tha...

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...


Latest News

With highest single-day spike of 32,695 cases, India's COVID-19 tally reaches 9,68,876

With the highest single-day spike of 32,695 cases and 606 deaths reported in the last 24 hours, Indias COVID-19 tally on Thursday reached 9,68,876, informed the Union Ministry of Health and Family Welfare on Thursday. The total number of CO...

Beijing reports no new domestically transmitted COVID-19 cases for 10 consecutive days

Beijing China, July 16 Xinhua ANI Beijing reported no new confirmed domestically transmitted COVID-19 cases on Wednesday July 15th, the municipal health commission said Thursday. This marked that the Chinese capital city had reported no new...

Four missing trekkers located in Uttarakhand; SDRF on rescue mission

Four trekkers who went missing on their way to Vasuki Tal from Kedarnath Temple have been located and all of them are safe, according to Uttarakhand Chief Ministers Office CMO on Thursday. Chief Minister has spoken to all of them and the SD...

US Senate Committee to vote on bill banning Tik Tok

A United States Senate committee is likely to vote on a bill next week from Republican Senator Josh Hawley that would ban federal employees from using the social media app TikTok on government-issued devices. The Senate Homeland Security an...

Give Feedback